江苏恒盛药业有限公司系江苏高科技股份制企业，投资方为(1)上海主板一上市公司及(2)南京一大型投资公司等，拥有精通国际国内医药业务的国际化及本土化的管理团队,现有员工300余人，并快速增长发展转型中。公司现有业务年销售额近3亿元，正实施新型生物医药投资项目，并推进综合制药采购、技术、cGMP制造、准入法规及国内外市场的一体化原料药和制剂的具备国际水准的业务转型，对呼吸道疾病及代谢性疾病治疗药品的业务进行创新及价值整合。业务范围包含苏州张家港市扬子江国际工业园区的制造及研发放大基地，上海徐汇区聚科高科技园区的商务研发中心，以及正并购中的其它医药业务。
      
      JiangsuHansynPharmaceuticalCo.,Ltdisahigh-techprivatepharmaceuticalorganizationinJiangsu,withshareholdersof(1)aShanghaistockexchangelistedcompany,(2)afund-management&investmentcompanyinNanjing,andothers.ItsassetsincludeamanufacturingsiteinZhangjiagangInternationalIndustrialPark,andaR&DandbusinesscenterinJukeHigh-techParkinXuhuidistrict,Shanghai.Itownsacoremanagementteamfrombothoverseasreturneesandlocaltalentsinpharmaceuticalindustry,withastaffofover300currentlyandunderrapidexpansion.ItsexistingrevenueisaboutRMB300M,withnewinvestmentsofmanufacturing+R&Dforactivepharmaceuticalingredientsisbeingexecuted,andpossibleacquisitionsongoing.ThebusinessfocusistoprovidetheoptimumintegratedservicesandproductsforRegulatedSourcing,ContractResearch&Development(CRO)andcGMPCustomManufacturing(CMO)topharmaceuticalindustry.Withitsexperienceandexpertiseinpharmaceuticalandchemistry,thecompanyisstrivingtooffervaluesynergiesandinnovationstocustomersviasustainablepartnershipinkeytherapeuticareasincludingrespiratory,metabolismanddiabetes.
      
      http://www.hspharm.cn/

展开全部